Pfizer Current Ratio 1986-2025 | PFE
Current and historical current ratio for Pfizer (PFE) from 1986 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Pfizer current ratio for the three months ending June 30, 2025 was 1.16.
| Pfizer Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2025-06-30 |
$43.70B |
$37.73B |
1.16 |
| 2025-03-31 |
$45.86B |
$36.45B |
1.26 |
| 2024-12-31 |
$50.36B |
$43.00B |
1.17 |
| 2024-09-30 |
$43.22B |
$43.21B |
1.00 |
| 2024-06-30 |
$37.83B |
$43.82B |
0.86 |
| 2024-03-31 |
$42.42B |
$40.50B |
1.05 |
| 2023-12-31 |
$43.33B |
$47.79B |
0.91 |
| 2023-09-30 |
$74.01B |
$31.14B |
2.38 |
| 2023-06-30 |
$73.35B |
$34.65B |
2.12 |
| 2023-03-31 |
$50.08B |
$36.56B |
1.37 |
| 2022-12-31 |
$51.26B |
$42.14B |
1.22 |
| 2022-09-30 |
$70.40B |
$44.31B |
1.59 |
| 2022-06-30 |
$67.47B |
$47.41B |
1.42 |
| 2022-03-31 |
$54.42B |
$39.27B |
1.39 |
| 2021-12-31 |
$59.69B |
$42.67B |
1.40 |
| 2021-09-30 |
$57.90B |
$41.80B |
1.39 |
| 2021-06-30 |
$48.81B |
$35.66B |
1.37 |
| 2021-03-31 |
$39.53B |
$26.65B |
1.48 |
| 2020-12-31 |
$35.07B |
$25.92B |
1.35 |
| 2020-09-30 |
$47.74B |
$34.15B |
1.40 |
| 2020-06-30 |
$46.42B |
$32.72B |
1.42 |
| 2020-03-31 |
$34.74B |
$33.89B |
1.03 |
| 2019-12-31 |
$32.80B |
$37.30B |
0.88 |
| 2019-09-30 |
$33.46B |
$36.97B |
0.91 |
| 2019-06-30 |
$47.07B |
$32.03B |
1.47 |
| 2019-03-31 |
$45.29B |
$29.42B |
1.54 |
| 2018-12-31 |
$49.93B |
$31.86B |
1.57 |
| 2018-09-30 |
$41.58B |
$29.01B |
1.43 |
| 2018-06-30 |
$37.30B |
$32.16B |
1.16 |
| 2018-03-31 |
$34.84B |
$27.37B |
1.27 |
| 2017-12-31 |
$41.14B |
$30.43B |
1.35 |
| 2017-09-30 |
$40.29B |
$28.22B |
1.43 |
| 2017-06-30 |
$36.39B |
$27.18B |
1.34 |
| 2017-03-31 |
$35.88B |
$24.86B |
1.44 |
| 2016-12-31 |
$38.95B |
$31.12B |
1.25 |
| 2016-09-30 |
$38.50B |
$34.76B |
1.11 |
| 2016-06-30 |
$43.85B |
$32.10B |
1.37 |
| 2016-03-31 |
$41.30B |
$28.74B |
1.44 |
| 2015-12-31 |
$43.80B |
$29.40B |
1.49 |
| 2015-09-30 |
$45.00B |
$27.85B |
1.62 |
| 2015-06-30 |
$51.72B |
$24.14B |
2.14 |
| 2015-03-31 |
$49.44B |
$20.22B |
2.45 |
| 2014-12-31 |
$55.60B |
$21.59B |
2.58 |
| 2014-09-30 |
$56.99B |
$19.92B |
2.86 |
| 2014-06-30 |
$58.29B |
$21.94B |
2.66 |
| 2014-03-31 |
$57.79B |
$24.79B |
2.33 |
| 2013-12-31 |
$56.24B |
$23.37B |
2.41 |
| 2013-09-30 |
$59.50B |
$20.37B |
2.92 |
| 2013-06-30 |
$61.44B |
$23.45B |
2.62 |
| 2013-03-31 |
$64.76B |
$27.54B |
2.35 |
| 2012-12-31 |
$64.83B |
$29.19B |
2.22 |
| 2012-09-30 |
$57.13B |
$29.13B |
1.96 |
| 2012-06-30 |
$58.77B |
$30.80B |
1.91 |
| 2012-03-31 |
$54.86B |
$27.09B |
2.03 |
| 2011-12-31 |
$60.82B |
$28.91B |
2.10 |
| 2011-09-30 |
$62.73B |
$27.86B |
2.25 |
| 2011-06-30 |
$60.48B |
$30.47B |
1.99 |
| 2011-03-31 |
$58.24B |
$29.17B |
2.00 |
| 2010-12-31 |
$61.01B |
$28.64B |
2.13 |
| 2010-09-30 |
$54.09B |
$24.17B |
2.24 |
| 2010-06-30 |
$51.10B |
$24.68B |
2.07 |
| 2010-03-31 |
$49.92B |
$25.92B |
1.93 |
| 2009-12-31 |
$61.67B |
$37.23B |
1.66 |
| 2009-09-30 |
$73.78B |
$23.99B |
3.08 |
| 2009-06-30 |
$71.55B |
$26.11B |
2.74 |
| 2009-03-31 |
$54.25B |
$23.34B |
2.32 |
| 2008-12-31 |
$43.08B |
$27.01B |
1.60 |
| 2008-09-30 |
$48.23B |
$21.50B |
2.24 |
| 2008-06-30 |
$48.65B |
$23.19B |
2.10 |
| 2008-03-31 |
$51.01B |
$21.68B |
2.35 |
| 2007-12-31 |
$46.85B |
$21.84B |
2.15 |
| 2007-09-30 |
$41.84B |
$14.33B |
2.92 |
| 2007-06-30 |
$41.62B |
$15.14B |
2.75 |
| 2007-03-31 |
$42.34B |
$13.30B |
3.18 |
| 2006-12-31 |
$47.66B |
$22.10B |
2.16 |
| 2006-09-30 |
$38.72B |
$17.69B |
2.19 |
| 2006-06-30 |
$40.99B |
$20.06B |
2.04 |
| 2006-03-31 |
$37.42B |
$19.67B |
1.90 |
| 2005-12-31 |
$46.84B |
$28.40B |
1.65 |
| 2005-09-30 |
$32.77B |
$20.40B |
1.61 |
| 2005-06-30 |
$33.57B |
$22.57B |
1.49 |
| 2005-03-31 |
$42.35B |
$28.95B |
1.46 |
| 2004-12-31 |
$39.09B |
$26.46B |
1.48 |
| 2004-09-30 |
$39.06B |
$25.24B |
1.55 |
| 2004-06-30 |
$36.69B |
$25.16B |
1.46 |
| 2004-03-31 |
$35.39B |
$24.64B |
1.44 |
| 2003-12-31 |
$30.68B |
$23.91B |
1.28 |
| 2003-09-30 |
$33.07B |
$21.66B |
1.53 |
| 2003-06-30 |
$34.74B |
$22.16B |
1.57 |
| 2003-03-31 |
$31.10B |
$18.75B |
1.66 |
| 2002-12-31 |
$24.78B |
$18.56B |
1.34 |
| 2002-09-30 |
$23.67B |
$18.40B |
1.29 |
| 2002-06-30 |
$22.39B |
$16.32B |
1.37 |
| 2002-03-31 |
$20.97B |
$14.73B |
1.42 |
| 2001-12-31 |
$19.21B |
$13.73B |
1.40 |
| 2001-09-30 |
$20.00B |
$13.04B |
1.53 |
| 2001-06-30 |
$19.60B |
$11.98B |
1.64 |
| 2001-03-31 |
$18.70B |
$10.87B |
1.72 |
| 2000-12-31 |
$17.19B |
$11.98B |
1.44 |
| 2000-09-30 |
$17.17B |
$12.34B |
1.39 |
| 2000-06-30 |
$15.82B |
$12.22B |
1.29 |
| 2000-03-31 |
$10.43B |
$7.48B |
1.40 |
| 1999-12-31 |
$11.19B |
$9.19B |
1.22 |
| 1999-09-30 |
$11.48B |
$9.09B |
1.26 |
| 1999-06-30 |
$11.15B |
$8.81B |
1.27 |
| 1999-03-31 |
$10.75B |
$7.75B |
1.39 |
| 1998-12-31 |
$9.93B |
$7.19B |
1.38 |
| 1998-09-30 |
$9.87B |
$7.26B |
1.36 |
| 1998-06-30 |
$8.26B |
$6.14B |
1.35 |
| 1998-03-31 |
$7.41B |
$5.68B |
1.30 |
| 1997-12-31 |
$6.82B |
$5.31B |
1.29 |
| 1997-09-30 |
$7.24B |
$5.78B |
1.25 |
| 1997-06-30 |
$7.34B |
$6.42B |
1.14 |
| 1997-03-31 |
$6.93B |
$5.78B |
1.20 |
| 1996-12-31 |
$6.47B |
$5.64B |
1.15 |
| 1996-09-30 |
$6.81B |
$6.20B |
1.10 |
| 1996-06-30 |
$6.49B |
$5.85B |
1.11 |
| 1996-03-31 |
$6.41B |
$5.48B |
1.17 |
| 1995-12-31 |
$6.15B |
$5.19B |
1.19 |
| 1995-09-30 |
$6.14B |
$5.80B |
1.06 |
| 1995-06-30 |
$5.98B |
$6.10B |
0.98 |
| 1995-03-31 |
$5.83B |
$5.78B |
1.01 |
| 1994-12-31 |
$5.79B |
$4.83B |
1.20 |
| 1994-09-30 |
$5.43B |
$4.14B |
1.31 |
| 1994-06-30 |
$5.17B |
$4.29B |
1.21 |
| 1994-03-31 |
$4.94B |
$3.75B |
1.32 |
| 1993-12-31 |
$4.73B |
$3.44B |
1.37 |
| 1993-09-30 |
$5.70B |
$4.15B |
1.37 |
| 1993-06-30 |
$5.75B |
$4.10B |
1.40 |
| 1993-03-31 |
$5.44B |
$3.62B |
1.50 |
| 1992-12-31 |
$5.39B |
$3.22B |
1.67 |
| 1992-09-30 |
$5.64B |
$3.22B |
1.75 |
| 1992-06-30 |
$5.00B |
$3.16B |
1.58 |
| 1992-03-31 |
$4.71B |
$3.05B |
1.55 |
| 1991-12-31 |
$4.81B |
$3.42B |
1.41 |
| 1991-09-30 |
$4.36B |
$3.23B |
1.35 |
| 1991-06-30 |
$4.36B |
$3.26B |
1.34 |
| 1991-03-31 |
$4.26B |
$2.83B |
1.51 |
| 1990-12-31 |
$4.44B |
$3.12B |
1.42 |
| 1990-09-30 |
$3.88B |
$2.68B |
1.45 |
| 1990-06-30 |
$3.96B |
$2.58B |
1.54 |
| 1990-03-31 |
$4.05B |
$2.35B |
1.72 |
| 1989-12-31 |
$4.51B |
$2.91B |
1.55 |
| 1989-09-30 |
$3.80B |
$2.32B |
1.64 |
| 1989-06-30 |
$3.77B |
$2.43B |
1.55 |
| 1989-03-31 |
$4.06B |
$2.16B |
1.88 |
| 1988-12-31 |
$4.10B |
$2.34B |
1.75 |
| 1988-09-30 |
$3.98B |
$2.05B |
1.94 |
| 1988-06-30 |
$4.08B |
$2.05B |
1.99 |
| 1988-03-31 |
$4.09B |
$1.87B |
2.18 |
| 1987-12-31 |
$4.10B |
$1.96B |
2.10 |
| 1987-09-30 |
$2.73B |
$1.49B |
1.84 |
| 1987-06-30 |
$2.68B |
$1.49B |
1.81 |
| 1987-03-31 |
$2.46B |
$1.22B |
2.01 |
| 1986-12-31 |
$2.96B |
$1.23B |
2.40 |
| 1985-12-31 |
$2.16B |
$0.96B |
2.25 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
